Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas

Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1

(2012) Marieke Aarts et al.   Cancer Discovery

WEE1 inhibition sensitizes osteosarcoma to radiotherapy

(2011) Jantine PosthumaDeBoer et al.   BMC CANCER

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

(2011) N. V. Rajeshkumar et al.   CLINICAL CANCER RESEARCH

WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe

(2011) P. C. De Witt Hamer et al.   CLINICAL CANCER RESEARCH

MK1775, a Selective Wee1 Inhibitor, Shows Single-Agent Antitumor Activity against Sarcoma Cells

(2011) J. M. Kreahling et al.   MOLECULAR CANCER THERAPEUTICS

Novel insights into maintaining genomic integrity: Wee1 regulating Mus81/Eme1

(2011) Yusé Martín et al.   Cell Division

Targeting the checkpoint kinase WEE1: Selective sensitization of cancer cells to DNA-damaging drugs

(2010) Paola Indovina et al.   CANCER BIOLOGY & THERAPY

MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil

(2010) Hiroshi Hirai et al.   CANCER BIOLOGY & THERAPY

Development and characterization of a conditionally transformed adult human osteoblastic cell line

(2010) Peter V.N. Bodine et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome

(2009) Lyndsay M. Murrow et al.   BREAST CANCER RESEARCH AND TREATMENT

Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

(2009) Shinji Mizuarai et al.   Molecular Cancer

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer

(2008) N Bucher et al.   BRITISH JOURNAL OF CANCER

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY